Emerging evidence positions that ER dysregulation serves as a key link between breast cancer and AD, with ERβ loss and ERα hyperactivation driving oncogenic and neurodegenerative processes, respectively (Bardin et al., 2004; Wang et al., 2016). Here, ESR2 is linked to breast carcinoma.